Spike Protein News and Research

RSS

Current monoclonal antibodies less potent against SARS-CoV-2 variants

Researchers at the New York University Grossman School of Medicine and Biohaven Pharmaceuticals found that the REGN10933 and REGN10987 combination was 9.1-fold less potent on the B.1.351 variant, which emerged in South Africa, and 16.2-fold less potent on mink cluster 5.

22 Feb 2021

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

Superspreader events trigger emergence of novel SARS-CoV-2 variants in USA

A team of scientists from the USA and Germany has recently studied the evolution of SARS-CoV-2 in a representative set of sequences from the USA collected between 2020 and 2021. The findings reveal that the viral genome has accumulated multiple mutations over time with only occasional loss of mutation. The main driving forces behind such genetic variations include widespread infection and superspreader events.

22 Feb 2021

Study profiles the nose to predict immune response during COVID-19

SARS-CoV-2 resides in mucous membranes, making it easy to detect viral load in the nasal cavities. An international group of researchers has characterized the immunological and diagnosis characteristics of patients who may have or are confirmed with SARS-CoV-2 infection. The team found a distinct nasal cytokine profile that could help identify patients at risk for high inflammatory responses to SARS-CoV-2 infection.

22 Feb 2021

Some SARS-CoV-2 variants evade mRNA vaccine-induced humoral immune, says study

Understanding how variants escape vaccine-boosted immune function is necessary to neutralizing SARS-CoV-2. An international team of researchers from MIT and Harvard University in the USA analyzed Pfizer and Moderna vaccines' effectiveness in neutralizing spike proteins from 10 different strains of SARS-CoV-2.

22 Feb 2021

Could an intranasal adjuvant to vaccines boost immunity against SARS-CoV-2 variants?

A research team from the University of Michigan Medical School, USA, developed a supplementary intranasal treatment to improve COVID-19 vaccine response and its effects on long-lasting immunity from other variants, such as the B.1.351 variant first found in South Africa.

22 Feb 2021

Disinfectants could be helping bacteria to become resistant

News-Medical speaks to Professor Robert Bragg about disinfectants and how they could be helping bacteria to become resistant.

22 Feb 2021

Gold nanoparticles investigated as part of in vitro tool for SARS-CoV-2 drug screening

Scientists have measured the interaction of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein with nano-gold colloids. These nanoparticles functionalized with the S protein have different spectroscopic signals allowing for new information about the protein to be extracted.

21 Feb 2021

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

The primary aim of any vaccine is to stimulate immune functions and confer long-lasting protection. A paper recently uploaded to the preprint server bioRxiv by Tong et al. (17th Feb 2021) describes a novel vaccine utilizing PIKA adjuvant and recombinant spike proteins against COVID-19 disease that promises the generation of potent neutralization antibodies, which potentially support immune responses for years.

21 Feb 2021

Proteases modulate SARS-CoV-2 spike protein activation and deactivation

A research paper recently uploaded to the preprint server bioRxiv by Platt et al. (17th Feb 2021) aimed to identify these enzymes by computational screening and molecular docking simulations, with cathepsins B, K, L, S, and V being highlighted as probable leads.

21 Feb 2021

Cissampelos pareira L. extracts demonstrate anti-SARS-CoV-2 activity in vitro

A team of scientists from India has recently investigated the antiviral potency of a traditional medicinal plant Cissampelos pareira L. in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The findings reveal that both whole-plant extracts and bioactive compounds can inhibit SARS-CoV-2 replication by modulating estrogen receptor 1 (ESR1) activity.

21 Feb 2021

Evolution of the spike gene of SARS-CoV-2 for human adaptation

Researchers have found a 96% similarity in nucleotide sequence between bat coronavirus (RaTG13), isolated from Rhinolophus affinis bats in China in 2013, and SARS-CoV-2 and ~97% amino acid similarity with the Spike (S) protein. This S protein performs two essential roles, i.e., mediates receptor-binding and membrane fusion. Hence, spike protein is regarded as a key coronavirus determinant of host tropism.

21 Feb 2021

Interval between doses of Oxford COVID-19 vaccine can be safely extended to 3 months, suggests study

A 3-month interval between doses of the Oxford COVID-19 vaccine results in higher vaccine efficacy than a 6-week interval, with the first dose offering 76% protection in the 3 months between doses.

20 Feb 2021

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

A new study reports the development of nanoantibodies (nAbs) – also called or nanobodiesTM or single-domain antibodies – that effectively bind the SARS-CoV-2 spike protein from the ancestral Wuhan variant as well as the recently detected UK and South African variants.

19 Feb 2021

Spike Protein News and Research

Current monoclonal antibodies less potent against SARS-CoV-2 variants

An overview of spike protein antigen COVID-19 vaccine candidates

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

Superspreader events trigger emergence of novel SARS-CoV-2 variants in USA

Study profiles the nose to predict immune response during COVID-19

Some SARS-CoV-2 variants evade mRNA vaccine-induced humoral immune, says study

Could an intranasal adjuvant to vaccines boost immunity against SARS-CoV-2 variants?

Disinfectants could be helping bacteria to become resistant

Gold nanoparticles investigated as part of in vitro tool for SARS-CoV-2 drug screening

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

Proteases modulate SARS-CoV-2 spike protein activation and deactivation

Cissampelos pareira L. extracts demonstrate anti-SARS-CoV-2 activity in vitro

Evolution of the spike gene of SARS-CoV-2 for human adaptation

Interval between doses of Oxford COVID-19 vaccine can be safely extended to 3 months, suggests study

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

COVID-19 and lung cancer have a common pathway, say researchers

Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses

Scientists use computer simulations to identify future targets for treatment of Covid-19

How does the SARS-CoV-2 E484K mutation increase viral fitness?

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News